Bulk Pharmaceutical API Sources for NORCEPT-E 1/35 21

Bulk Pharmaceutical API Sources for NORCEPT-E 1/35 21

Vendor	Vendor Homepage	Vendor Sku	API Url
THE BioTek		bt-277561
BenchChem		B1679912
J&H Chemical Co.,ltd		JH278055
RR Scientific		R201384
EvitaChem		evt-277561

NORCEPT-E 1/35 21: Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape for sourcing bulk Active Pharmaceutical Ingredient (API) for NORCEPT-E 1/35 21. It identifies key manufacturers, evaluates their production capabilities, and assesses regulatory compliance, providing critical intelligence for supply chain strategy.

What is NORCEPT-E 1/35 21 and its API?

NORCEPT-E 1/35 21 is a fixed-dose combination oral contraceptive. Its active pharmaceutical ingredients are Ethinylestradiol and Levonorgestrel. Ethinylestradiol is a synthetic estrogen, and Levonorgestrel is a synthetic progestin. The "1/35" designation typically refers to 0.035 mg of Ethinylestradiol and 0.15 mg of Levonorgestrel per tablet, though specific product formulations can vary. The API for NORCEPT-E 1/35 21 therefore comprises bulk Ethinylestradiol and bulk Levonorgestrel.

Who are the Primary Manufacturers of Ethinylestradiol API?

The production of Ethinylestradiol API is concentrated among a limited number of global manufacturers. These companies often possess specialized synthesis capabilities and adhere to stringent quality control measures.

• Central Coast Pharmaceuticals: Based in the United States, Central Coast Pharmaceuticals is a significant producer of steroid hormones, including Ethinylestradiol. They operate cGMP-compliant manufacturing facilities and have a long-standing presence in the API market. Their production capacity is estimated to be in the metric ton range annually.
• Hovione Farmaciência: This Portuguese API manufacturer is a key global supplier, known for its complex chemical synthesis expertise. Hovione has established cGMP facilities and robust quality management systems. They supply Ethinylestradiol API to numerous pharmaceutical companies worldwide.
• Ajinomoto Bio-Pharma Services: While primarily known for biologics, Ajinomoto also produces select small molecule APIs. Their facilities in the U.S. and Europe are FDA and EMA approved. Their contribution to Ethinylestradiol supply, while possibly smaller in volume compared to specialized steroid producers, is noted.
• Zhejiang Xianju Pharmaceutical: A Chinese manufacturer with substantial API production capacity. Zhejiang Xianju Pharmaceutical is a major player in steroid API manufacturing, including Ethinylestradiol. They have obtained certifications from various regulatory bodies, including EDQM and an FDA Establishment Inspection Report (EIR).

Table 1: Ethinylestradiol API Manufacturers and Key Attributes

Manufacturer	Primary Location	Specialization	Regulatory Approvals (Examples)	Estimated Annual Capacity (Metric Tons)	Notes
Central Coast Pharmaceuticals	USA	Steroid Hormones	FDA, EDQM	5-10	Long-standing industry player.
Hovione Farmaciência	Portugal	Complex Synthesis	FDA, EMA, PMDA	7-12	Global supplier with strong quality focus.
Ajinomoto Bio-Pharma Services	USA/Europe	Small Molecule APIs	FDA, EMA	2-5	Diversified portfolio, integrated services.
Zhejiang Xianju Pharmaceutical Co.	China	Steroid APIs	FDA, EDQM, WHO-GMP	15-25	Large-scale producer, cost-competitive.

What are the Primary Manufacturers of Levonorgestrel API?

Levonorgestrel API manufacturing is similarly concentrated, with a few key players dominating the global supply.

• Bayer AG: As a major pharmaceutical innovator in contraceptives, Bayer has in-house manufacturing capabilities for Levonorgestrel API. Their production facilities are subject to rigorous internal and external regulatory oversight. Specific capacity details are proprietary but are understood to be substantial to meet their global product demand.
• IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): An Indian API manufacturer with a significant presence in the global market. IOLCP produces a wide range of APIs, including Levonorgestrel. Their facilities are cGMP compliant and have been inspected by regulatory authorities including the US FDA.
• Amneal Pharmaceuticals: While known for its finished dosage forms, Amneal also engages in API development and manufacturing. Their capabilities include the synthesis of complex molecules like Levonorgestrel at their cGMP-compliant sites.
• Tianjin Pharmaceutical: A Chinese pharmaceutical company that manufactures various APIs. They are known for producing Levonorgestrel API and have established export markets, adhering to international quality standards.

Table 2: Levonorgestrel API Manufacturers and Key Attributes

Manufacturer	Primary Location	Specialization	Regulatory Approvals (Examples)	Estimated Annual Capacity (Metric Tons)	Notes
Bayer AG	Germany	In-house Production	FDA, EMA, GMP	Proprietary	Vertically integrated, internal supply assurance.
IOL Chemicals and Pharmaceuticals Ltd.	India	Diverse APIs	FDA, WHO-GMP, EDQM	10-18	Strong export presence, cost-effective.
Amneal Pharmaceuticals	USA	Complex Molecules	FDA	3-7	Focus on quality and regulatory compliance.
Tianjin Pharmaceutical	China	API Manufacturing	GMP, ISO	8-15	Growing presence in international markets.

What are the Regulatory Requirements for API Sourcing?

Sourcing bulk APIs for pharmaceutical products like NORCEPT-E 1/35 21 necessitates strict adherence to global regulatory standards.

• Current Good Manufacturing Practices (cGMP): All API manufacturers must comply with cGMP regulations as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. These regulations cover facility design, equipment, personnel training, process validation, quality control, and record-keeping.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains detailed information about the manufacturing process, quality control, and stability of the API. Pharmaceutical companies referencing these DMFs in their drug product applications can ensure their API source meets regulatory scrutiny.
• Certificate of Analysis (CoA): Each batch of API must be accompanied by a CoA, which details the results of quality control testing, confirming that the batch meets pre-defined specifications for identity, purity, strength, and other critical attributes.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on various aspects of API development and manufacturing, including Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients). Compliance with these guidelines is essential for global market access.
• Audits and Inspections: Pharmaceutical companies regularly conduct audits of their API suppliers to ensure ongoing compliance with cGMP and contractual agreements. Regulatory agencies also perform routine inspections of API manufacturing facilities.

What is the Impact of Supply Chain Disruptions on API Sourcing?

The global API supply chain is susceptible to various disruptions, which can significantly impact the availability and cost of NORCEPT-E 1/35 21.

• Geopolitical Instability: Conflicts, trade disputes, and changes in national policies can restrict the movement of raw materials and finished APIs, leading to shortages.
• Natural Disasters: Earthquakes, floods, and pandemics (e.g., COVID-19) can halt manufacturing operations, damage facilities, and disrupt logistics. The COVID-19 pandemic highlighted the fragility of global supply chains, leading to API shortages for various drugs.
• Regulatory Changes: New or updated regulations in manufacturing countries or importing countries can require significant investment in compliance, potentially leading to temporary supply interruptions or increased costs.
• Raw Material Availability: The synthesis of complex APIs like Ethinylestradiol and Levonorgestrel relies on a consistent supply of precursor chemicals. Shortages or price volatility of these raw materials can directly affect API production.
• Quality Control Issues: Any failure in quality control or a recall of an API batch can lead to immediate supply gaps and necessitate the qualification of alternative suppliers, a process that can take months.

To mitigate these risks, companies are increasingly pursuing strategies such as dual sourcing, regionalizing supply chains, and holding larger API inventories.

How Can Companies Ensure a Robust API Supply for NORCEPT-E 1/35 21?

Establishing and maintaining a secure supply of Ethinylestradiol and Levonorgestrel APIs requires a strategic approach.

• Supplier Qualification and Auditing: Implement a rigorous process for vetting potential API manufacturers. This includes thorough due diligence on their regulatory history, quality systems, financial stability, and manufacturing capabilities. Regular audits are crucial to ensure ongoing compliance.
• Dual Sourcing Strategy: Identify and qualify at least two independent, reliable API manufacturers for each API component. This diversifies risk and provides flexibility in the event of a disruption with a primary supplier.
• Geographic Diversification: Source APIs from manufacturers located in different geographical regions to reduce exposure to localized geopolitical or environmental risks.
• Contractual Agreements: Negotiate comprehensive supply agreements that clearly define quality specifications, delivery schedules, pricing, intellectual property rights, and contingency plans for supply disruptions.
• Early Engagement with Manufacturers: Foster close working relationships with key API suppliers. Early communication regarding projected demand, potential capacity constraints, and planned process changes can prevent future issues.
• Inventory Management: Implement a robust inventory management system that balances the cost of holding inventory against the risk of stockouts. Consider safety stock levels for critical APIs.
• Monitoring Regulatory Landscape: Continuously monitor regulatory updates in all relevant markets and from all qualified suppliers to anticipate and adapt to any new compliance requirements.

Key Takeaways

• The supply of Ethinylestradiol and Levonorgestrel APIs for NORCEPT-E 1/35 21 is concentrated among a select group of global manufacturers, with significant players in the United States, Europe, India, and China.
• Regulatory compliance, particularly cGMP and comprehensive DMFs, is paramount for API sourcing.
• Supply chain disruptions, stemming from geopolitical factors, natural disasters, and raw material availability, pose significant risks to API availability and cost.
• A robust API supply strategy involves rigorous supplier qualification, dual sourcing, geographic diversification, strong contractual agreements, and proactive inventory management.

FAQs

1. What is the typical lead time for qualifying a new API supplier for Ethinylestradiol or Levonorgestrel? Qualifying a new API supplier typically involves a comprehensive process including initial assessment, site audits, quality agreement finalization, and process validation. This can range from 6 to 18 months, depending on the complexity of the API and the rigor of the qualification process.

2. How can a company assess the financial stability of an API manufacturer? Financial stability can be assessed through reviewing publicly available financial reports (if applicable), credit reports from agencies like Dun & Bradstreet, and direct inquiries about their financial health and investment in manufacturing capabilities.

3. What are the risks associated with single-sourcing an API? Single-sourcing an API exposes a company to significant risks, including supply interruption due to manufacturing issues at the sole supplier, price increases, quality failures, and the inability to meet demand during periods of high market growth or unexpected surges in demand.

4. Are there any emerging regions for Ethinylestradiol or Levonorgestrel API production? While established regions like China and India remain dominant, there is ongoing investment in API manufacturing capabilities in other regions. However, for highly specialized steroid APIs like Ethinylestradiol and Levonorgestrel, major shifts in production concentration are not immediately anticipated without significant new investment in specialized infrastructure and expertise.

5. What is the role of the European Directorate for the Quality of Medicines & HealthCare (EDQM) in API sourcing? The EDQM grants Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP demonstrates that an API complies with the relevant European Pharmacopoeia monograph and indicates that the quality is controlled by the manufacturer through robust EDQM-approved manufacturing processes. This is a significant indicator of API quality and regulatory acceptance within Europe and in countries that recognize CEPs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-research-and-development/good-manufacturing-practice-gmp

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. ICH.

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/certificates-suitability-monographs-european-pharmacopoeia